中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
News
TUL Highlights
2026-09-07
UBT251 INJECTION COMPLETED FIRST PARTICIPANT DOSING IN PHASE III CLINICAL STUDY FOR OVERWEIGHT OR OBESITY IN CHINA
Learn More
2026-09-07
Significant Progress in Innovative Drug R&D and Continued Globalization Efforts Profit Attributable to Owners of the Company Reached Approximately RMB347.6 Million
Learn More
2026-08-12
FDA APPROVAL OF IND FOR THE GROUP’S PRODUCT UBT48128 TABLETS
Learn More
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
All News
Select Year
2026
2025
2024
The United Laboratories (Inner Mongolia) Co., Ltd. Successfully Completed Simultaneous Inspections by Germany's BJV and the U.S. FDA
2026-06-08
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT TUL108 FOR INJECTION
2026-05-20
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT UBT38006 INJECTION
2026-05-08
ESG Report 2025
2026-04-30
FDA APPROVAL OF IND FOR GROUP’S PRODUCT TUL321 CAPSULES
2026-04-29
APPROVAL FOR CLINICAL TRIAL OF THE GROUP’S PRODUCT DUPILUMAB INJECTION
2026-04-23
The United Laboratories International Holdings Limited Announces 2025 Annual Results
2026-03-26
Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
2026-03-26
APPROVAL FOR MARKETING OF THE GROUP'S PRODUCT INSULIN DEGLUDEC INJECTION
2026-03-10
Prev
1
2
3
4
5
...
17
Next
WeChat
Official
Account
To Top
粤公网安备44040402000348号
